Review



bjab  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ATCC bjab
    Epigallocatechin-3-gallate (EGCG) reduced cell viability in human herpesvirus <t>8</t> <t>(HHV8)-harboring</t> primary effusion lymphoma (PEL) cells. ( A ) PEL cells (BCBL-1 and BC-1) were treated with EGCG at the concentrations indicated for 24 h; ( B ) Sensitivity of BCBL-1, BC-1, <t>BJAB</t> cells and PBMCs to EGCG. BCBL-1, BC-1, BJAB cells and PBMCs were treated with 20 μg/mL of EGCG for 24 h. Cell viability was determined by the trypan blue exclusion assay. The cells in supplemented medium were used as a control. The values represent mean ± SE of three independent experiments and are presented as the percentage of the control. * p < 0.05 and ** p < 0.01 indicate significant differences between the control and EGCG-treated cells.
    Bjab, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bjab/product/ATCC
    Average 90 stars, based on 18 article reviews
    bjab - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Epigallocatechin-3-Gallate Suppresses Human Herpesvirus 8 Replication and Induces ROS Leading to Apoptosis and Autophagy in Primary Effusion Lymphoma Cells"

    Article Title: Epigallocatechin-3-Gallate Suppresses Human Herpesvirus 8 Replication and Induces ROS Leading to Apoptosis and Autophagy in Primary Effusion Lymphoma Cells

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms19010016

    Epigallocatechin-3-gallate (EGCG) reduced cell viability in human herpesvirus 8 (HHV8)-harboring primary effusion lymphoma (PEL) cells. ( A ) PEL cells (BCBL-1 and BC-1) were treated with EGCG at the concentrations indicated for 24 h; ( B ) Sensitivity of BCBL-1, BC-1, BJAB cells and PBMCs to EGCG. BCBL-1, BC-1, BJAB cells and PBMCs were treated with 20 μg/mL of EGCG for 24 h. Cell viability was determined by the trypan blue exclusion assay. The cells in supplemented medium were used as a control. The values represent mean ± SE of three independent experiments and are presented as the percentage of the control. * p < 0.05 and ** p < 0.01 indicate significant differences between the control and EGCG-treated cells.
    Figure Legend Snippet: Epigallocatechin-3-gallate (EGCG) reduced cell viability in human herpesvirus 8 (HHV8)-harboring primary effusion lymphoma (PEL) cells. ( A ) PEL cells (BCBL-1 and BC-1) were treated with EGCG at the concentrations indicated for 24 h; ( B ) Sensitivity of BCBL-1, BC-1, BJAB cells and PBMCs to EGCG. BCBL-1, BC-1, BJAB cells and PBMCs were treated with 20 μg/mL of EGCG for 24 h. Cell viability was determined by the trypan blue exclusion assay. The cells in supplemented medium were used as a control. The values represent mean ± SE of three independent experiments and are presented as the percentage of the control. * p < 0.05 and ** p < 0.01 indicate significant differences between the control and EGCG-treated cells.

    Techniques Used: Trypan Blue Exclusion Assay, Control



    Similar Products

    bjab  (ATCC)
    90
    ATCC bjab
    Epigallocatechin-3-gallate (EGCG) reduced cell viability in human herpesvirus <t>8</t> <t>(HHV8)-harboring</t> primary effusion lymphoma (PEL) cells. ( A ) PEL cells (BCBL-1 and BC-1) were treated with EGCG at the concentrations indicated for 24 h; ( B ) Sensitivity of BCBL-1, BC-1, <t>BJAB</t> cells and PBMCs to EGCG. BCBL-1, BC-1, BJAB cells and PBMCs were treated with 20 μg/mL of EGCG for 24 h. Cell viability was determined by the trypan blue exclusion assay. The cells in supplemented medium were used as a control. The values represent mean ± SE of three independent experiments and are presented as the percentage of the control. * p < 0.05 and ** p < 0.01 indicate significant differences between the control and EGCG-treated cells.
    Bjab, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bjab/product/ATCC
    Average 90 stars, based on 1 article reviews
    bjab - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human b cell line bjab  (ATCC)
    90
    ATCC human b cell line bjab
    Epigallocatechin-3-gallate (EGCG) reduced cell viability in human herpesvirus <t>8</t> <t>(HHV8)-harboring</t> primary effusion lymphoma (PEL) cells. ( A ) PEL cells (BCBL-1 and BC-1) were treated with EGCG at the concentrations indicated for 24 h; ( B ) Sensitivity of BCBL-1, BC-1, <t>BJAB</t> cells and PBMCs to EGCG. BCBL-1, BC-1, BJAB cells and PBMCs were treated with 20 μg/mL of EGCG for 24 h. Cell viability was determined by the trypan blue exclusion assay. The cells in supplemented medium were used as a control. The values represent mean ± SE of three independent experiments and are presented as the percentage of the control. * p < 0.05 and ** p < 0.01 indicate significant differences between the control and EGCG-treated cells.
    Human B Cell Line Bjab, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human b cell line bjab/product/ATCC
    Average 90 stars, based on 1 article reviews
    human b cell line bjab - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Epigallocatechin-3-gallate (EGCG) reduced cell viability in human herpesvirus 8 (HHV8)-harboring primary effusion lymphoma (PEL) cells. ( A ) PEL cells (BCBL-1 and BC-1) were treated with EGCG at the concentrations indicated for 24 h; ( B ) Sensitivity of BCBL-1, BC-1, BJAB cells and PBMCs to EGCG. BCBL-1, BC-1, BJAB cells and PBMCs were treated with 20 μg/mL of EGCG for 24 h. Cell viability was determined by the trypan blue exclusion assay. The cells in supplemented medium were used as a control. The values represent mean ± SE of three independent experiments and are presented as the percentage of the control. * p < 0.05 and ** p < 0.01 indicate significant differences between the control and EGCG-treated cells.

    Journal: International Journal of Molecular Sciences

    Article Title: Epigallocatechin-3-Gallate Suppresses Human Herpesvirus 8 Replication and Induces ROS Leading to Apoptosis and Autophagy in Primary Effusion Lymphoma Cells

    doi: 10.3390/ijms19010016

    Figure Lengend Snippet: Epigallocatechin-3-gallate (EGCG) reduced cell viability in human herpesvirus 8 (HHV8)-harboring primary effusion lymphoma (PEL) cells. ( A ) PEL cells (BCBL-1 and BC-1) were treated with EGCG at the concentrations indicated for 24 h; ( B ) Sensitivity of BCBL-1, BC-1, BJAB cells and PBMCs to EGCG. BCBL-1, BC-1, BJAB cells and PBMCs were treated with 20 μg/mL of EGCG for 24 h. Cell viability was determined by the trypan blue exclusion assay. The cells in supplemented medium were used as a control. The values represent mean ± SE of three independent experiments and are presented as the percentage of the control. * p < 0.05 and ** p < 0.01 indicate significant differences between the control and EGCG-treated cells.

    Article Snippet: BJAB (ATCC HB-136) cells are HHV8-negative and EBV-negative human lymphoblastoid cells.

    Techniques: Trypan Blue Exclusion Assay, Control